Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
128 hedge funds and large institutions have $149M invested in Mersana Therapeutics in 2024 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 33 increasing their positions, 40 reducing their positions, and 11 closing their positions.
155% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 11
13% more funds holding
Funds holding: 113 → 128 (+15)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.41% less ownership
Funds ownership: 3.78% → 3.38% (-0.41%)
18% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 40
32% less capital invested
Capital invested by funds: $219M → $149M (-$70.3M)
82% less call options, than puts
Call options by funds: $356K | Put options by funds: $2.02M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$8.79M |
| 2 |
6CM
683 Capital Management
New York
|
+$1.48M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.43M |
| 4 |
BlackRock
New York
|
+$1.21M |
| 5 |
Millennium Management
New York
|
+$1.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$16.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$8.26M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$3M |
| 4 |
Goldman Sachs
New York
|
-$2.39M |
| 5 |
VA
VR Adviser
New York
|
-$2.21M |
MRSN Hedge Fund Activity: Q4 2024 in Review
128 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q4 2024, worth a combined $149M — down 32% from $219M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new MRSN positions and 11 closed out — a net gain of 17 holders — while 33 added to existing stakes and 40 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $8.79M. The largest seller was EcoR1 Capital, cutting an estimated $16.6M.
- 128 institutional investors held Mersana Therapeutics (MRSN) as of Q4 2024, up from 113 in Q3 2024.
- Funds reported $149M of Mersana Therapeutics stock for Q4 2024, down 32% quarter-over-quarter.
- 28 funds opened new Mersana Therapeutics positions in Q4 2024 and 11 closed out, a net change of +17 holders.
- The largest Mersana Therapeutics buyer in Q4 2024 was Novo Holdings A/S, an estimated $8.79M added.
- The largest Mersana Therapeutics seller in Q4 2024 was EcoR1 Capital, an estimated $16.6M sold.
Based on aggregated 13F filings for Q4 2024.